Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies Corporation (Nasdaq: DVAX) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. CEO Ryan Spencer will present at the event. The on-demand presentation will be accessible starting May 24, 2022, at 7:00 a.m. E.T., through the Company's website. Dynavax focuses on developing innovative vaccines, including the HEPLISAV-B® vaccine for Hepatitis B and CpG 1018 adjuvant used in COVID-19 vaccines. For more details, visit dynavax.com.

Dynavax Technologies Corporation (DVAX) reported a strong first quarter of 2022 with total revenues of $114.0 million, a 37% increase from $83.3 million in Q1 2021. The HEPLISAV-B® vaccine generated $20.8 million, a 151% rise year-over-year, while CpG 1018® adjuvant revenue reached $91.5 million, up 23%. The company remains on track for a second consecutive year of profitability and maintains its 2022 guidance for CpG 1018 revenue of at least $550 million. Additionally, Dynavax is advancing its clinical pipeline, expecting key data readouts later this year.

Dynavax Technologies Corporation (Nasdaq: DVAX) will release its first quarter 2022 financial results on May 5, 2022, after U.S. market close. A conference call and live audio webcast are scheduled for the same day at 4:30 p.m. ET. Investors can access the webcast via the company's website or by calling (866) 420-4066. The company focuses on developing innovative vaccines, including HEPLISAV-B for hepatitis B and CpG 1018 adjuvant for various vaccines.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the granting of restricted stock units (RSUs) covering 28,250 shares to five new employees as part of their employment incentive. The RSUs, granted on April 1, 2022, have an exercise price of $11.26 per share, matching the stock's closing price on the grant date. These RSUs will vest at a rate of one-third per year and comply with Nasdaq Listing Rule 5635(c)(4). Dynavax continues to focus on developing vaccines against infectious diseases, including its approved hepatitis B vaccine.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the granting of nonstatutory stock options to purchase 33,250 shares and restricted stock units (RSUs) for 48,250 shares to a new employee, effective March 7, 2022. The exercise price of the options is $9.87 per share, equal to the stock's closing price on the grant date. The stock options will vest over three years, while the RSUs will vest one-third per year. These grants comply with Nasdaq Rule 5635(c)(4) and form part of the 2021 Inducement Award Plan.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced on March 3, 2022, the grant of restricted stock units (RSUs) covering 16,000 shares to two newly-hired employees, effective March 1, 2022. The exercise price for these stock options is set at $12.21 per share, matching the closing price on the grant date. The RSUs will vest one-third annually, contingent on continued service. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan, aimed at attracting new talent.

Dynavax Technologies (DVAX) reported a record total revenue of $439.4 million for 2021, a significant rise from $46.6 million in 2020. Key revenue drivers included HEPLISAV-B with $61.9 million and CpG 1018 adjuvant supply generating $375.2 million. The company anticipates at least $550 million in CpG 1018 revenue in 2022. Dynavax ended the year with approximately $546 million in cash. Positive momentum is expected with new clinical developments and increased market share opportunities stemming from CDC recommendations. Net income reached $76.7 million, marking a profitable year.

Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 2:50 p.m. E.T. The chat will feature Ryan Spencer, CEO, and Kelly MacDonald, CFO. Interested parties can access the presentation via the 'Events & Presentations' page on the company's website. Dynavax is known for developing HEPLISAV-B®, a Hepatitis B vaccine, and is advancing its CpG 1018 adjuvant for various infectious diseases.

Dynavax Technologies (Nasdaq: DVAX) announced it will report its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call and live audio webcast will follow at 4:30 p.m. ET. The company focuses on developing innovative vaccines, including its approved hepatitis B vaccine, HEPLISAV-B. Dynavax is also advancing its CpG 1018 adjuvant for various infectious diseases and collaborating on vaccines for COVID-19 and other diseases.